LXEOHealthcare · BiotechnologyThe 10 Wall Street analysts covering Lexeo Therapeutics, Inc. hold a median 12-month price target of $20 — +539.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 28 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Lexeo Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (81): Sales and profits are climbing, and climbing faster than before.
Momentum (18): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on LXEO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +539.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Sept 2026 | Leerink Partners | Maintains | Outperform | $15 |
| 25 June 2026 | JP Morgan | Maintains | Overweight | $12 → $9.00 |
| 25 June 2026 | JP Morgan | Maintains | Overweight | — |
| 11 May 2026 | Chardan Capital | Maintains | Buy | — |
| 13 Jan 2026 | Chardan Capital | Maintains | Buy | — |
| 13 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Dec 2025 | Raymond James | Initiates | Strong Buy | — |
| 11 Dec 2025 | Chardan Capital | Maintains | Buy | — |
| 1 Dec 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
| 20 Nov 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
| 6 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 5 Nov 2025 | Chardan Capital | Maintains | Buy | $17 |
| 21 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Oct 2025 | Guggenheim | Initiates | Buy | — |
| 7 Oct 2025 | Chardan Capital | Maintains | Buy | — |
| 7 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Oct 2025 | Leerink Partners | Maintains | Outperform | — |
| 15 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 15 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Aug 2025 | Leerink Partners | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
LXEO appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 28 Oct 2026, Lexeo Therapeutics, Inc. returned −68.9% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 85% of US stocks
Cheaper than 73% of US stocks
Cheaper than 64% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 22% of US stocks
Higher than 15% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Lexeo Therapeutics, Inc. has a market value of $256.9M and an enterprise value of $51.9M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$87.3M.
Diluted earnings per share, trailing twelve months: $−1.15.
Free cash flow in the twelve months to 30 June 2026: −$88.7M.
Trailing P/E: −1.7×; forward P/E: −2.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Lexeo Therapeutics, Inc. employs 63 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Lexeo Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
At the Chardan Healthcare Conference, Lexeo Therapeutics outlined upcoming clinical and regulatory milestones for its gene therapy programs in Friedreich's ataxia cardiomyopathy and PKP2-associated arrhythmogenic cardiomyopathy.
Why it matters — The milestones provide LXEO watchers with an update on the company's planned development steps for these programs.
Lexeo Therapeutics outlined its approach to evaluating LX2020, an investigational AAVrh10-based gene therapy for PKP2-associated arrhythmogenic cardiomyopathy. The update came ahead of an expected clinical and regulatory update later this quarter.
Why it matters — The evaluation approach and forthcoming update may provide LXEO watchers with information about the program’s development.
Lexeo Therapeutics discussed clinical assessment and unmet need in PKP2 arrhythmogenic cardiomyopathy in a transcript published by Seeking Alpha.
Why it matters — The discussion provides LXEO watchers with context on clinical assessment and unmet need in the condition.
Lexeo Therapeutics announced it will host an educational investor event on clinically meaningful arrhythmias in PKP2-ACM on October 21, 2026, at 1:00 p.m. ET. The event will feature a discussion with Narinder Bhalla, M.D.
Why it matters — The event will provide LXEO watchers with discussion of clinical endpoints and outcome measures in PKP2-ACM.
Lexeo Therapeutics announced it will participate in a fireside chat at Chardan’s 10th Annual Healthcare Conference on October 20, 2026, at 9:30 a.m. ET. The event will be webcast live on the Events & Presentations tab of the company’s investor website.
Why it matters — LXEO watchers can follow the company’s conference participation through the announced live webcast.
The 10 Wall Street analysts covering Lexeo Therapeutics, Inc. have a median 12-month price target of $20, with estimates ranging from $9 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Lexeo Therapeutics, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lexeo Therapeutics, Inc. 27 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Lexeo Therapeutics, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (81 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +539.0% from the last close, and Ticker Nerd's factor model ranks Lexeo Therapeutics, Inc. 27 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Lexeo Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LXEO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $30 over the next 12 months.
Lexeo Therapeutics, Inc. returned -68.9% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company focused on developing gene therapy candidates for hereditary and acquired diseases with high unmet medical need.
The most recent item we track (MarketBeat, 25 Oct 2026): "Lexeo Therapeutics Maps Gene Therapy Milestones, Eyes Key 2027 Readout". At the Chardan Healthcare Conference, Lexeo Therapeutics outlined upcoming clinical and regulatory milestones for its gene therapy programs in Friedreich's ataxia cardiomyopathy and PKP2-associated arrhythmogenic cardiomyopathy.
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company focused on developing gene therapy candidates for hereditary and acquired diseases with high unmet medical need. Lexeo Therapeutics concentrates on genetically defined cardiovascular conditions and APOE4-associated Alzheimer’s disease, using AAV-based programs designed to address the underlying causes of disease. Its current pipeline includes therapies such as LX2006 for Friedreich’s ataxia cardiomyopathy, LX2020 for PKP2-related arrhythmogenic cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer’s disease. The company operates as a biotechnology developer rather than a commercial drug maker, with its work centered on research, clinical development, and advancing precision medicines through early- and mid-stage testing. Based in New York City, Lexeo Therapeutics plays a specialized role in the genetic medicine market by targeting serious conditions where conventional treatments remain limited.
CEO Mr. R. Nolan Townsend M.B.A. · 63 employees · United States · https://www.lexeotx.com
